Excerpt from the CEO's comment in the half-year report:
"The last six months have been a challenging time for our research and development-oriented business, and this is reflected in our financial figures. Happily, our successful issue after the end of the period (during the month of July) has secured the company's finances going forward according to plan. This success shows the trust that our investors have in the company and the hopes that are placed on our projects. We hope to continue to demonstrate our ability to deliver ground-breaking solutions. The resources that we have secured through the issue will be crucial to continue our work in developing innovative products based on our nanotechnology, and now with a primary focus on the StemCART project."
January -
- Net sales amounted to
SEK 0 (0). -
Operating profit amounted to
SEK -3,349,005 (-2,554,201 -
Earnings per share after tax amounted to
SEK -0.17 (-0.17). - Profit per average number of shares after tax amounted to -0.17 (-0.17)
The report is published at www.clinescientific.com/financial-reports
The company is listed on the Nasdaq First North Growth Market.
For more information, please contact:
CEO
Chairman
CFO Håkan Bengtsson, +46 (0)705-558902, hakan.bengtsson@clinescientific.com
Argongatan 2 C Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline's unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.
https://news.cision.com/cline/r/half-year-report-for-cline-scientific-ab--publ--556867-8238--for-the-period-january-1---june-30--202,c3823698
https://mb.cision.com/Main/12114/3823698/2252052.pdf
(c) 2023 Cision. All rights reserved., source